CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Altre lingue Charles River Laboratories International, Inc.

Azioni

CRL

US1598641074

Mercato chiuso - Nyse Altri mercati azionari 22:00:02 25/04/2024			Variaz. 5gg	Var. 1 gen.
227,8 ^USD	-4,85%		+0,11%	-3,63%

25/04	FibroBiologics, Inc. prevede di collaborare con Charles River Laboratories per produrre sferoidi a base di fibroblasti	CI
24/04	Charles River Laboratories deposita un supplemento alla dichiarazione definitiva di delega presso la Securities and Exchange Commission	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	25/04
Charles River Laboratories International : Proxy Supplement Filed April 24, 2024	24/04
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission	24/04
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally	22/04
Charles River Laboratories International : 2023 Corporate Citizenship Report	22/04
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing	16/04
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing	16/04
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call	15/04
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call	12/04
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology	11/04
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology	11/04
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies	09/04
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics	09/04
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics	09/04
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus	04/04
Charles River to Perform Plasmid Production for Ship of Theseus	04/04
Charles River to Perform Plasmid Production for Ship of Theseus	04/04
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement	04/04
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024	01/04
Charles River Laboratories International, Inc Receives a Shareholder Proposal from People for the Ethical Treatment of Animals	29/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Charles River Laboratories International, Inc.

Azioni

CRL

US1598641074

Altre lingue

Filtri